Voyager Therapeutics financials
$2.64−2.22%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.2M | $2.6M | $15.3M | $13.4M | $5.2M | $6.5M | $6.3M | $24.6M | $29.6M | $19.5M | $90.1M | $4.6M |
| Gross profit | $3.2M | $2.6M | $15.3M | $13.4M | $5.2M | $6.5M | $6.3M | $24.6M | $29.6M | $19.5M | $90.1M | $4.6M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$26.4M | -$30.3M | -$29.9M | -$30.6M | -$36.6M | -$34.7M | -$38.3M | -$13.8M | -$15.0M | -$16.2M | $54.1M | -$29.5M |
| Net income | -$24.5M | -$28.2M | -$27.4M | -$27.9M | -$33.4M | -$30.8M | -$34.5M | -$9.0M | -$10.1M | -$11.3M | $56.4M | -$25.9M |
| Net margin | −773.2% | −1088.8% | −178.8% | −208.7% | −642.0% | −476.0% | −549.3% | −36.7% | −34.3% | −58.1% | 62.6% | −561.4% |
| Diluted EPS | $-0.40 | $-0.47 | $-0.47 | $-0.47 | $-0.57 | $-0.53 | $-0.59 | $-0.16 | $-0.18 | $-0.20 | $1.16 | $-0.59 |
| EBITDA | -$25.5M | -$29.3M | -$28.9M | -$29.7M | -$35.6M | -$33.7M | -$37.3M | -$12.6M | -$13.6M | -$15.0M | $55.4M | -$28.6M |
| Operating cash flow | -$25.8M | -$33.4M | -$30.3M | -$31.0M | -$33.3M | -$37.9M | -$14.5M | -$28.0M | -$31.6M | $58.8M | -$23.8M | -$21.1M |
| Free cash flow | -$25.8M | -$33.4M | -$30.9M | -$31.3M | -$34.4M | -$38.6M | -$14.7M | -$28.2M | -$32.5M | $56.6M | -$24.5M | -$21.8M |
| Diluted shares | 60.5M | 59.5M | 58.9M | 58.8M | 58.7M | 58.3M | 58.0M | 57.9M | 57.7M | 57.1M | 48.7M | 43.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $35.8M | $43.3M | $65.3M | $45.1M | $43.9M | $74.8M |
| Short-term investments | $80.6M | $98.2M | $131.1M | $163.8M | $171.7M | $161.3M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $197.8M | $219.3M | $252.3M | $288.3M | $322.1M | $353.2M |
| Total liabilities | $43.4M | $45.7M | $56.2M | $68.5M | $78.2M | $80.5M |
| Shareholders' equity | $154.4M | $173.7M | $196.1M | $219.8M | $243.9M | $272.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology